

## Brilliant Violet 421™ anti-mouse CD25 Antibody

<b>Catalog# / Size</b>	102033 / 125 µL 102043 / 50 µg 102034 / 500 µL
<b>Clone</b>	PC61
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	IL-2R $\alpha$ , Ly-43, p55, Tac
<b>Isotype</b>	Rat IgG1, $\lambda$
<b>Description</b>	CD25 is a 55 kD glycoprotein also known as the low affinity IL-2R $\alpha$ , Ly-43, p55, or Tac. It is expressed on activated T and B cells, thymocyte subsets, pre-B cells, and T regulatory cells. In association with CD122 (IL-2R $\beta$ ) and CD132 (common $\gamma$ chain), CD25 forms the high affinity signaling IL-2 receptor.

### Product Details

---

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	IL-2-dependent cytolytic mouse T-cell clone B6.1
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
<b>Preparation</b>	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
<b>Concentration</b>	µg sizes: 0.2 mg/mL µL sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our <a href="#">Concentration and Expiration Lookup</a> or <a href="#">Certificate of Analysis</a> online tools.)
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	<p>Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a>. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.125 µg per million cells in 100 µl volume. For immunofluorescent staining using µl sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.</p> <p>Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.</p> <p><a href="#">Learn more about Brilliant Violet™.</a></p> <p>This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.</p>
<b>Excitation Laser</b>	Violet Laser (405 nm)
<b>Application Notes</b>	Additional reported applications (for the relevant formats) include: immunoprecipitation <sup>1,2</sup> , <i>in vitro</i> blocking of IL-2 binding to low- and high-affinity receptors <sup>1-4</sup> , growth inhibition of IL-2-dependent T-cell lines <sup>1-4</sup> , <i>in vivo</i> depletion of CD25 <sup>+</sup> CD4 <sup>+</sup> Treg cells <sup>5-8,10</sup> , and immunohistochemical staining of acetone-fixed frozen sections <sup>2</sup> . PC61 antibody recognizes a different epitope than 3C7 antibody

(Cat. No. 101902). For *in vivo* studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 102040) with endotoxin < 0.01 EU/μg, Azide-Free, 0.2 μm filtered.

## Application References

(PubMed link indicates BioLegend citation)

1. Lowenthal JW, *et al.* 1985. *Nature* 315:669. (IP, Block)
2. Ceredig R, *et al.* 1985. *Nature* 314:98. (IP, IHC, Block)
3. Lowenthal JW, *et al.* 1985. *J. Immunol.* 135:3988. (Block)
4. Moreau JL, *et al.* 1987. *Eur. J. Immunol.* 17:929. (Block)
5. Takahashi T, *et al.* 2000. *J. Exp. Med.* 192:303. (Deplete)
6. Onizuka S, *et al.* 1999. *Cancer Res.* 59:3128. (Deplete)
7. Lei TC, *et al.* 2005. *Blood* 105:4865. (Deplete)
8. Pasare C, *et al.* 2004. *Immunity* 21:733. (Deplete)
9. León-Ponte M, *et al.* 2007. *Blood* 109:3139.
10. Cao OW, *et al.* 2007. *Blood* doi:10.1182/blood-2007-02-073304. (Deplete)
11. Benson MJ, *et al.* 2007. *J. Exp. Med.* doi:10.1084/jem.20070719.
12. Liu F, *et al.* 2011. *Arch Toxicol.* 85:1383. [PubMed](#)
13. Anguela XM, *et al.* 2013. *Diabetes.* 62:551. [PubMed](#)

## Product Citations

1. Ramakrishna C, *et al.* 2019. *Nat Commun.* 10:2153. [PubMed](#)
2. Haratani K, *et al.* 2019. *J Clin Invest.* 130:374. [PubMed](#)
3. Wang D, *et al.* 2018. *Immunity.* 48:659. [PubMed](#)
4. Delacher M, *et al.* 2021. *Immunity.* 54(4):702-720.e17. [PubMed](#)
5. Pokrovskii M, *et al.* 2020. *EMBO J.* 39:e104159. [PubMed](#)
6. Trott DW, *et al.* 2021. *Geroscience.* 43:1331. [PubMed](#)
7. Sugimoto C, *et al.* 2022. *Elife.* 11:. [PubMed](#)
8. Ayasoufi K, *et al.* 2020. *Brain.* 3629:143. [PubMed](#)
9. Alissafi T, *et al.* 2020. *Cell Metabolism.* 32(4):591-604.e7. [PubMed](#)
10. Miyazaki M *et al.* 2017. *Immunity.* 46(5):818-834 . [PubMed](#)
11. Ramos CV, *et al.* 2020. *Cell Reports.* 32(3):107910. [PubMed](#)
12. Yin Q, *et al.* 2021. *Proc Natl Acad Sci U S A.* 118: . [PubMed](#)
13. Friedman DJ, *et al.* 2021. *Cancer Immunol Res.* 9:952. [PubMed](#)
14. Takeshita Y, *et al.* 2021. *Neurol Neuroimmunol Neuroinflamm.* 8:. [PubMed](#)
15. Vogel A, *et al.* 2022. *STAR Protoc.* 3:101653. [PubMed](#)
16. Galle-Treger L, *et al.* 2016. *Nat Commun.* 7:13202. [PubMed](#)
17. Efremova M, *et al.* 2018. *Nat Commun.* 9:32. [PubMed](#)
18. Klepsch V, *et al.* 2018. *Nat Commun.* 9:1538. [PubMed](#)
19. de Picciotto S, *et al.* 2022. *Nat Commun.* 13:3866. [PubMed](#)
20. Compeer EB, *et al.* 2018. *Nat Commun.* 9:1597. [PubMed](#)
21. Zhu S, *et al.* 2022. *EBioMedicine.* 80:104060. [PubMed](#)
22. Damgaard RB *et al.* 2016. *Cell.* 166(5):1215-1230 . [PubMed](#)
23. Fan MY *et al.* 2018. *Cell reports.* 25(5):1204-1213 . [PubMed](#)
24. Coley WD *et al.* 2018. *F1000Research.* 2018 Mar 14 [revised 2018 Jan 1] 0.5125. [PubMed](#)
25. Vogel A, *et al.* 2022. *Cell Rep.* 38:110420. [PubMed](#)
26. Knox T, *et al.* 2019. *Sci Rep.* 9:6136. [PubMed](#)
27. Field CS, *et al.* 2020. *Cell Metab.* 31:422. [PubMed](#)
28. Miao Y *et al.* 2019. *Cell.* 177(5):1172-1186 . [PubMed](#)
29. Schick V, *et al.* 2014. *Gut.* 63:1469. [PubMed](#)

## RRID

AB\_10895908 (BioLegend Cat. No. 102033)  
AB\_2562611 (BioLegend Cat. No. 102043)  
AB\_11203373 (BioLegend Cat. No. 102034)

## Antigen Details

---

<b>Structure</b>	Forms high affinity IL-2R with IL-2Rβ (CD122) and IL-2Rγ (CD132), 55 kD
<b>Distribution</b>	Activated T cells and B cells, thymocyte subset, pre-B cells, T regulatory cells
<b>Function</b>	IL-2 receptor
<b>Ligand/Receptor</b>	IL-2
<b>Cell Type</b>	B cells, T cells, Thymocytes, Tregs
<b>Biology Area</b>	Immunology
<b>Molecular Family</b>	CD Molecules, Cytokine/Chemokine Receptors

## Antigen References

1. Taniguchi T, *et al.* 1993. *Cell* 73:5-8.
2. Waldmann TA. 1991. *J Biol Chem.* 266:2681-4.
3. Read S, *et al.* 2000. *J Exp Med.* 192:295-302.
4. Lowenthal JW, *et al.* 1985. *J Immunol.* 135:3988-94.

## Gene ID

[16184](#)


## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats

APC anti-mouse CD25, Biotin anti-mouse CD25, FITC anti-mouse CD25, PE anti-mouse CD25, PE/Cyanine5 anti-mouse CD25, Purified anti-mouse CD25, PE/Cyanine7 anti-mouse CD25, Alexa Fluor® 488 anti-mouse CD25, Alexa Fluor® 647 anti-mouse CD25, Pacific Blue™ anti-mouse CD25, Alexa Fluor® 700 anti-mouse CD25, APC/Cyanine7 anti-mouse CD25, PerCP/Cyanine5.5 anti-mouse CD25, PerCP anti-mouse CD25, Brilliant Violet 421™ anti-mouse CD25, Brilliant Violet 605™ anti-mouse CD25, Brilliant Violet 650™ anti-mouse CD25, Ultra-LEAF™ Purified anti-mouse CD25, Brilliant Violet 510™ anti-mouse CD25, PE/Dazzle™ 594 anti-mouse CD25, Brilliant Violet 711™ anti-mouse CD25, Brilliant Violet 785™ anti-mouse CD25, Alexa Fluor® 594 anti-mouse CD25, APC/Fire™ 750 anti-mouse CD25, TotalSeq™-A0097 anti-mouse CD25, KIRAVIA Blue 520™ anti-mouse CD25, TotalSeq™-B0097 anti-mouse CD25, TotalSeq™-C0097 anti-mouse CD25, Spark NIR™ 685 anti-mouse CD25 Antibody, PE/Fire™ 640 anti-mouse CD25, Spark YG™ 581 anti-mouse CD25, APC/Fire™ 810 anti-mouse CD25

## Product Data



C57BL/6 mouse splenocytes were stained with CD4 FITC and CD25 (clone PC61) Brilliant Violet 421™ (top) or rat IgG1, κ Brilliant Violet 421™ isotype control (bottom).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587